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Background: This study was designed to investigate epidermal growth factor receptor (EGFR) mutation types
affecting lung cancer treatment in patients in Xinjiang, China. We detected and analyzed differences in the EGFR
mutation points of Uighur and Han patients with lung adenocarcinoma. We examined 181 specimens of lung
adenocarcinoma tissue embedded with paraffin (76 Uighur and 105 Han patients) for mutations in the EGFR gene
in exon 18-21 by the amplification refractory mutation system (ARMS) method. We used the chi-square statistical
method to analyze the relationship between mutations and patients’ clinical parameters.
Results: EGFR somatic mutations were detected in 59 of 181 cases (32.6%). The mutation rate was higher in Han
patients (45.7%) than in Uighur patients (15.8%) (P < 0.001). The main mutation types were the exon 19 deletion
and the L858R point mutation in exon 21. In Han patients we found 21 (44.7%) cases of exon 19 deletion, 24
(51.1%) cases of L858R in exon 21, 1 case (2.1%) with mutations in both exon 19 and exon 21, and 1 case (2.1%)
with T790 mutation in exon 20. In Uighur patients we found 8 (66.7%) cases of exon 19 deletion and 4 (33.3%)
cases of L858R in exon 21.
Conclusions: In comparing these groups, the exon 19 deletion was more common than L858R in exon 21 in
Uighur patients. In Han patients, EGFR-sensitive mutations occurred in female, never-smoking patients with
well-differentiated tumors; but for Uighur patients only smoking history showed an obvious correlation.
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Lung cancer has become the leading cause of cancer
death worldwide, and the incidence of lung cancer is still
on the rise in most countries. Five-year overall survival
is only 10% in China. In 2010, an estimated population
of 222,500 patients was newly diagnosed with lung can-
cer and bronchiolar carcinoma (116,750 males and
105,770 females), with 157,300 deaths (86,200 males and
71,100 females) [1].
Recently, molecular targeting therapies against epider-
mal growth factor receptor (EGFR) have gained increasing* Correspondence: 1615369202@qq.com
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unless otherwise stated.recognition in the treatment of lung cancer. Treatment
with EGFR tyrosine kinase inhibitor (TKI), e.g. gefitinib
and/or erlotinib, in advanced lung cancer has proven itself
effective. Multiple clinical studies [2-4] have suggested
that female Asian patients with adenocarcinoma who had
never smoked had superior efficacy with gefitinib and er-
lotinib, particularly those with bronchioloalveolar carcin-
oma (BAC). Study results demonstrated that the EGFR
tyrosine kinase inhibitor gefitinib (Brand name Iressa®)
achieved a response rate of more than 80% in mutant
tumors, but was basically ineffective in wild-type tumors
without mutations [5]. These results were confirmed
post-publication by scientists in other countries. There-
fore, guiding EGFR-TKI therapy with EGFR gene statusis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 2 Relationship between EGFR genetic mutation and
clinicopathological features in patients of Han ethnic
group
Characteristics EGFR
Mutations Wild χ2 P
Sex Male 19 37 5.696 0.017
Female 28 21
Age ≤65 24 47 0.282 0.595
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practical strategy.
Research shows that EGFR TKI therapy efficacy and
EGFR gene mutation status are significantly related to the
patients’ ethnic or regional origin and can vary vastly [6].
For example, the exon 21 mutation predominated in
Taiwan, and the exon 19 mutation predominated in
Guangdong region, but no significant difference was noted
between mutations in these two exons in Beijing [7-9].
Most of the studies in this field have focused on popula-
tions in Europe and East Asia, but rarely on those in the
Middle East and Middle Asia. Xinjiang is located at the
junction of the Eurasian continent, and recently the inci-
dence of lung cancer among the local Uighur population
has increased year by year. Because EGFR gene mutation
status in Uighur patients with lung adenocarcinoma is not
known, we designed this study to provide genetic evidence
for effective treatment with EGFR-TKI therapy.
Results and Discussion
Patient characteristics
Among 181 lung adenocarcinoma patients, the EGFR
mutation rate was 32.6%. In the group of 76 Uighur pa-
tients, the EGFR mutation rate was 15.8%; and in the
group of 105 Han patients, the mutation rate was 44.8%.
For all types of EGFR mutations, the rates were signifi-
cantly lower in the Uighur patients than in the Han pa-
tients (P < 0.001) (Table 1). The two main types of
mutation were an exon 19 deletion mutation and L858R
(base substitution mutation in codon 858). The percentage
of Uighur patients with the exon 19 mutation (66.7%) is
higher than that with the exon 21 mutation (33.3%). By
contrast, the percentage of Han patients with the exon 19
mutation (44.7%) is slightly lower than that with the exon
21 mutation (51.1%). In the Han group, one patient had
both exon 19 and exon 21 mutations (2.1%), and one pa-
tient had a T790 mutation in exon 20 (2.1%).
Relationship between EGFR genetic mutation and
clinicopathological features in adenocarcinoma patients
of Han ethnic group
In the Han group, female patients had a significantly
higher EGFR genetic mutation rate as compared to maleTable 1 EGFR genetic mutation rates in lung
adenocarcinoma patients of Uighur and Han ethnic
groups









76 64(84.2) 12(15.8) P < 0.001
Han ethnic group 105 58(55.2) 47(44.8)patients, with statistically significant difference between
them (P < 0.05). Patients with no smoking history had a
significantly higher EGFR genetic mutation rate as com-
pared to smoking patients, with statistically significant
difference between them (P < 0.05). Patients with well-
differentiated tumors had significantly higher EGFR gen-
etic mutation rates as compared to patients with poorly
differentiated tumors, with statistically significant differ-
ence between them (P < 0.05). No statistically significant
correlations were found between EGFR genetic mutation
rate and either the patients’ age group or staging (P > 0.05)
(Table 2) [2].
Relationship between EGFR genetic mutation and
clinicopathological features in adenocarcinoma patients
of Uighur ethnic group
Uighur patients with no smoking history had a signifi-
cantly higher EGFR genetic mutation rate as compared
to smoking patients, with statistically significant difference
between them (P < 0.05). When we analyzed the relation-
ship between EGFR genetic mutations and clinicopatho-
logical features in adenocarcinoma patients, we found no
correlations in terms of sex, age groups, staging and
tumor differentiation (P > 0.05) (Table 3) [3].
EGFR gene mutation can lead to amplification and
overexpression of EGFR protein as well as to other car-
cinogenic mechanisms of EGFR tyrosine kinase activity
disorder. Inappropriate activation of EGFR tyrosine kin-
ase can promote tumor angiogenesis, tumor cell prolifer-
ation, adhesion, invasion and metastasis. In theory,
specific blocking of the receptors can inhibit tumor for-
mation and angiogenesis, and this theory has been con-
firmed in clinical studies [5,6]. However, in a small>65 18 16
Smoking Yes 18 34 4.289 0.034
No* 29 24








*No smoking is defined as: previous total amount of smoking fewer than
100 cigarettes.
Table 3 Relationship between EGFR genetic mutation and
clinicopathological features in patients of Uighur ethnic
group
Characteristics EGFR
Mutations Wild χ2 P
Sex Male 7 42 0.235 0.628
Female 5 22
Age ≤65 8 41 0.09 0.764
>65 4 25
Smoking Yes 3 38 4.806 0.028
No* 9 26




Well-differentiated 10 36 3.102 0.078
Poorly differentiated 2 28
*No smoking is defined as: previous total amount of smoking fewer than
100 cigarettes.
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that of 15 Uighur patients with chemotherapy failure in
treatment of non-small cell lung cancer who received
molecular targeted drugs, only 2 of the patients showed
stable disease, while 13 patients showed progressive dis-
ease. This result sharply contrasts with the satisfactory
effect of targeted drugs in the clinical research of lung
cancer elsewhere in China, and we hypothesized that the
difference may indicate a geographical and ethnic vari-
ation in the incidence and type of mutation.
Research shows that EGFR mutations in adenocarcin-
oma in different ethnic groups varied substantially.
Schmid et al. [10] and Kris et al. [11] found the rate of
Caucasian EGFR mutations in lung cancer is about 7%
-17%. In a study of 202 lung cancer patients, Li et al.
[12] found that the rate of Han lung adenocarcinoma
EGFR mutation was 75.3%. Han [13] and Hsu et al. [14]
further showed that the rate of EGFR mutations in lung
adenocarcinoma patients of East Asian ethnicities is
about 30% -62%. In this study, the Uighur lung adeno-
carcinoma EGFR mutation rate was slightly higher than
that reported in the literature on Caucasian populations
( [2,5,15], 3-13%), and was significantly lower than that
of the local Han cases (15.8% vs 44.8%) [12,16,17]. The
rates of EGFR mutations in lung adenocarcinoma
showed a gradually increasing trend from Europe to the
East Asian continent through the geographical distribu-
tion of these ethnic groups: the Han ethnic group is
from the East Asian continent, Caucasians are from the
European continent, and Uighurs live between Europe
and the East Asian continent. Further study has con-
firmed that different racial genetics decide and influence
the prognosis and response to treatment. Uighur lungcancer patients with targeted therapy are associated with
lower mutation rates.
Research shows that tumor response to erlotinib is
greater in patients with exon 19 mutation compared
with patients with exon 21 mutation [18]. In our study,
the Uighur group’s mutation rate in exon 19 was higher
than that in exon 21 (66.7% vs 33.3%), which is similar
to Caucasian population [18]. The Han patients, how-
ever, had a slightly lower percentage of exon 19 muta-
tions than exon 21 mutations (44.7% vs. 51.1%). The
insertion mutation in exon 20 was not found in the
Uighur patients. In the Uighur population the overall ef-
fect of EGFR TKI therapy may be better than in the Han
population.
Previous reports indicate that EGFR mutation is
closely related to age, sex, smoking status, and tumor
differentiation. EGFR mutations are common in older,
female, non-smoking patients with well-differentiated tu-
mors (especially bronchioloalveolar carcinoma) [12,17,18].
Our study’s findings are in accordance with these reports
in the Han group: EGFR mutation associated with sex,
smoking history, and the degree of tumor differentiation.
In the Uighur group, EGFR mutations were correlated
with smoking history. The relationship between gene mu-
tation rate and sex or degree of tumor differentiation is
not clear, perhaps because the Uighur patients in our
study were mostly male and were a small group.
Conclusion
The EGFR mutation rate in Uighur patients with lung
adenocarcinoma is relatively lower than in Han patients,
perhaps because of differences in race and region.
Uighur patients’ mutation ratio is close to that reported
in Caucasian patients, which may be the main reason for
poor treatment effectiveness in Uighur patients. Genetic
testing for mutations in Uighur patients before treat-
ment could prevent waste of therapeutic resources and
could specify targeted drug therapy. In cases of limited
resources, where no EGFR gene detection is available
and the patient shows intolerance to chemotherapy,
smoking history is a reference index. Because of the
small number of patients in this study, the relationship
between other clinical factors and EGFR mutation re-
mains to be verified by larger-scale studies.
Methods
Study participants and tissue samples
The tissue samples examined in this study were col-
lected by biopsy from November 2011 to January 2014
in Xinjiang Tumor Hospital, and all were diagnosed by
pathology. Specimens indicating adenocarcinoma of the
lung were paraffin-embedded. The study participants
were 76 Uighur patients (49 males and 27 females, ages
46- to 78-years-old, with median age 57 years) and 105
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years-old, with median age 53 years). AJCC TNM sta-
ging criteria were used to rate the disease as either
stage ≤ IIIa or > IIIa. We used H&E staining to divide
the specimens into two groups: well-differentiated tu-
mors and poorly differentiated tumors. The study was
reviewed and approved by the Institutional Ethics
Committee at Xinjiang Tumor Hospital. All patients
signed informed consent forms to participate in this
study and to give permission for the use of their tissue.Sample collection and DNA extraction
We collected samples and extracted DNA from 5- to 8-mm
slices of paraffin section, stored at room temperature. The
samples were determined by pathologic diagnosis to con-
tain tumor tissue and were preserved for no more than
2 years. We used DNA extraction kit (QIAGEN,
Germany), and we dissolved the extracted DNA in
Tris-HCl (10 mmol/L, pH 8.0). After sample quality
was checked by UV spectrophotometer (Amoy Diag-
nostics Co. Ltd, China), we added Tris-HCl solution
(10 mmol/L, pH 8.0) to adjust DNA concentration to
10 ng/μL and 2 ng/μL standby.ARMS
Real-time PCR amplified by the amplification refractory
mutation system (ARMS) method was used to detect
mutations in the EGFR gene exons 18-21. All samples
were amplified by Strata Gene MX3000P real-time PCR
instrument (Amoy Diagnostics Co. Ltd, China) accord-
ing to kit instructions, with each test designed with posi-
tive and negative control groups. If the Ct value = 0, or
Ct value > 30, the experiment will result in wild type.
The reaction conditions were as follows: 1 cycle of fluores-
cence PCR pre-degeneration in 95°C for 5 min; 15 cycles
degeneration in 95°C for 25 s, 64°C for 20 s, 72°C for 20 s;
and 31 cycles 93°C degeneration for 25 s, 60°C for 35 s,
72°C for 20 s.Statistical analysis
Data was analyzed using statistical software SPSS 18.
Chi-square test was used to compare differences in muta-
tions between the two groups as well as the relationship
between patients’ clinical features and EGFR mutations.
Probability value was obtained from two-sided tests, with
statistical significance defined as P < 0.05.
Abbreviations
ARMS: Amplification refractory mutation system; BAC: Bronchioloalveolar
carcinoma; EGFR: Epidermal growth factor receptor; TKI: Tyrosine kinase
inhibitor.
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